About BioVie

BioVie Inc. is a clinical-stage company developing transformative therapies to overcome unmet medical needs in chronic debilitating conditions.

In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2 study for the treatment of refractory ascites with top-line results expected in early 2022. It is administered as a patent-pending liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not available in the US or Japan.

In neurodegenerative disease, BioVie recently acquired the assets of NeurMedix Inc., including NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance. Both are drivers of Alzheimer’s and Parkinson’s diseases. The FDA has authorized a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028). An estimated six million Americans suffer from Alzheimer’s. BioVie is planning to initiate this trial in mid-2021 and targeting primary completion in late 2022. NE3107 and related compounds are globally patented first-in-class small molecules with additional potential to treat certain cancers.

Forward Looking Statements
This website contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, and assumptions that could cause BioVie’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements.
MORE
Sign-up to follow our progress
* indicates required
9120 Double Diamond Parkway
Suite 1400
Reno, NV 89521
(775) 888-3162

Email: info@biovieinc.com
Web: www.bioviepharma.com
© Copyright 2012 - 2021 | BioVie Inc. | ALL RIGHTS RESERVED |
 SITE MAP |
  PRIVACY POLICY |